Prevention of Osteoporotic Hip Fracture

Similar documents
Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Osteoporosis and fractures

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Assessment and Treatment of Osteoporosis Professor T.Masud

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

Fragility Fracture Liaison Program Bridging the gap between the Publics and Private interface in management of osteoporosis after fragility fracture

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Osteoporosis/Fracture Prevention

Page 1

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Osteoporosis Agents Drug Class Prior Authorization Protocol

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Presenter: 翁家嫻 Venue date:

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

1

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

What is Osteoporosis?

John J. Wolf, DO Family Medicine

Update on Osteoporosis 2016

AACE/ACE Osteoporosis Treatment Decision Tool

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Management of postmenopausal osteoporosis

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Quality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture

Training Course in Sexual and Reproductive Health Research Geneva, February Osteoporosis. Prof René Rizzoli M.D.

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

BONIVA (ibandronate sodium)

Men and Osteoporosis So you think that it can t happen to you

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT

Summary. Background. Diagnosis

Osteoporosis Management

OSTEOPOROSIS IN INDONESIA

Vasu Pai FRACS, Nat Board, MCh, M.S

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010

Building Bone Density-Research Issues

July 2012 CME (35 minutes) 7/12/2016

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Cortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly

Osteoporosis. Definition

Submission to the National Institute for Clinical Excellence on

SERMS, Hormone Therapy and Calcitonin

PROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE

Skeletal Manifestations

Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital

An Update on Osteoporosis Treatments

OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION

Osteoporosis Update. Greg Summers Consultant Rheumatologist

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Pathway from Fracture or Risk Factor to Treatment

Osteoporosis. Treatment of a Silently Developing Disease

Osteoporosis. Skeletal System

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

Trends in Glucocorticoid-Induced Osteoporosis Management Among Seniors in Ontario,

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Osteoporosis. Overview

All about. Osteoporosis

Effective Health Care

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

Osteoporosis. Information leaflet. This information is also available on request in other formats by phoning

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 October 2012

Talking to patients with osteoporosis about initiating therapy

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Disclosures Fractures:

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

New Developments in Osteoporosis: Screening, Prevention and Treatment

SpongeBone Menopants*

Osteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist

Keeping old bones from breaking: The diagnosis, prevention, and treatment of osteoporosis

Hot Topics in Osteoporosis and Fracture Prevention

Summary of the risk management plan by product

Download slides:

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C

Long term Sequelae in Natural and Surgical Menopause

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

TYMLOS (abaloparatide)

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases

Pharmacy Management Drug Policy

Chapter 39: Exercise prescription in those with osteoporosis

Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck

Differentiating Pharmacological Therapies for Osteoporosis

Medical Director Update

Conquering the Epidemic of Fractures: A Challenge for 21 st Century Clinicians. Objectives. Dr. Lappe has no conflicts to disclose.

Understanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.

Bisphosphonate Step Therapy Criteria

The recent publication of guidance from the National

Updates in Osteoporosis

Current Issues in Osteoporosis

Le linee guida: Indicazioni terapeutiche

Clinical Practice. Presented by: Internist, Endocrinologist

Pharmacy Management Drug Policy

Closing the Care Gap in Osteoporosis ICE Conference 2015

Prevent the next fracture. GP Guide

Transcription:

Prevention of Osteoporotic Hip Fracture Dr Law Sheung Wai 8th July 2007 Associate Consultant Spine team / Orthopedic Rehabilitation Department of Orthopedics and Traumatology NTE Cluster 1

Objectives Problems of Geriatric Hip Fracture Importance of prevention Level of prevention Mechanism of injuries and Fractures Strategy of prevention Secondary prevention

Incidence of 3 Fractures 4000 80 Vertebrae Annual Fracture Incidence, per 100,000 3000 2000 1000 Youngest BB Oldest baby boomers 70 75 Hip Wrist 0 35 45 55 65 75 85+ Next 5 to 25 years Age

Projected number of osteoporotic hip fractures worldwide 3250 Projected to reach 3.250 million in Asia by 2050 742 668 Total number of hip fractures: 1950 = 1.66 million 2050 = 6.26 million 378 629 400 1950 2050 600 1950 2050 100 1950 2050 1950 2050 Estimated number of hip fractures: (1000s) Adapted from Cooper et al, Osteoporos Int. 1992; 2:285-9

Consequences of hip fracture One year after hip fracture Patients (%) Death within one year 20% Permanent disability 30% Unable to walk independently 40% Unable to carry out at least one independent activity of daily living 80% Cooper. Am J Med 1997; 103(2A):12s-19s.

2002 2000 End result 2004

Prevention Primary Prevention Prevention of first fracture Secondary Prevention Prevention of subsequent fracture 7

Intrinsic -General degeneration -Balance -Medical problems Extrinsic -Environmental hazard Interaction with environment (e.g. risky behavioral Fall 8

Extrinsic Environment Intrinsic Age Muscle weakness Previous falls Gait / balance Visual Arthritis Cognitive impairment Depression Poly-pharmacy Risk taking behavior NEJM 2002

Elderly with osteoporosis.. Progressive kyphosis Compensatory mechanism

12

13

14

Extrinsic factors 15

16

Fall 1. Orientation of fall 2.protective responses 3.Local shock absorbers Insufficient 4.Bone strength Insufficient Hip Fracture Journal of Geronotology 1989 Vol 44,M104-111 17

Orientation of fall Hip fracture is different from colles fracture 18

Fall Orientation of fall protective responses Local shock absorbers Insufficient Bone strength Insufficient Hip Fracture Drugs 20

Bone strength is more than BMD young elderly Images from L. Mosekilde, Technology and Health Care. 1998 Image courtesy of David Dempster

22

Screening for osteoporosis 23

24

Pharmacological agents for treatment of osteoporosis Effective therapies are widely available and can reduce vertebral, hip and other fractures by 30% to 65%, even in patients who have already suffered a fracture

Pharmacological agents shown to reduce fracture risk Bisphosphonates Alendronate (FOSAMAX ) Risedronate (ACTONEL ) Ibandronate Hormone (BONVIVA therapy ) Zolendronate Estrogen / progestin (ACLASTA ) SERMs Raloxifene (EVISTA ) Stimulators of bone formation rh-pth (FORTEO ) Mixed mode of action Strontium ranelate (PROTELOS )

Effect on vertebral fracture risk Osteoporosis With prior fractures Osteoporosis Effect on non-vertebral fracture risk With prior fractures Alendronate + + NA + (incl. hip) Risedronate + + NA + (incl. hip) Ibandronate NA + NA + HRT + + + + Raloxifene + + NA NA Teriparatide and PTH Strontium ranelate NA + NA + + + + (incl. hip) + (incl. hip) NA, No evidence available; +, effective drug ; a women with a prior vertebral fracture Adapted from Boonen S. et al. 2005; Osteoporos Int; 16:239-54

Hip protectors ======

Hip Protectors protective devices against hip fractures Protective Garments comprise of: Pressurized pants Protective pads on lateral sides

Different options in market AHIP protectors, Safe hip et Same principle external and direct protection to the hip region

Same Problem Compliance rate: about 40% annually dropping from 70% in autumn to 20% in summer

Secondary prevention 2002 2000 End result 2004

Klotzbuecher et al. J Bone Miner Res 2000; 15:721-727 Prior fracture increases the risk of subsequent fracture Site of prior fracture Hip Spine Forearm Minor fracture Hip 2.3 2.3 1.9 2.0 Risk of subsequent fracture Spine Forearm Minor fracture 2.5 1.4 1.9 4.4 1.4 1.8 1.7 3.3 2.4 1.9 1.8 1.9 A prior fracture increases the risk of new fracture 2- to 5-fold

Risk of second hip fracture Incidence of second hip fracture. A population based study Osteoporosis International 2007 April 18 Cumulative risk one year ; 5.08 % second year ; 8.11 % At the time of second fracture -Osteoporosis diagnosed : 23% -Bisphonspahte : 16% -Calcium : 20% -Vit D : 16 %

Optimal care of the fragility fracture patient Diagnosis of fragility fracture Identify fragility fracture & underlying disease, incorporate into existing workup Influences treatment plan from the onset Fracture management Stabilize patient, pain relief, fracture care Rehabilitation Minimize dependence, maximize mobility Secondary prevention Treat and monitor underlying disease, prevent future fractures

Secondary Prevention of fracture

Intrinsic Extrinsic Strategy Accidental ( trip slip etc..) 14% Un-anticipated Physiological 8% Anticipated Physiological 78% ++++ Preventive Education +++ Protective Medical risk reduction +++ ++ ++ Case findings Risk reduction Protective Preventive Rehabilitation

Thanks